Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02107014 · ClinicalTrials.gov registry record · NA
Low Dose Naltrexone (LDN) Immune Monitoring
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT02107014 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 9 participants.
The verdict
NCT02107014, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.
Interventions
- DRUG Low Dose Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02107014
The ClinicalTrials.gov registry entry for NCT02107014 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Low Dose Naltrexone is the first listed.
NCT02107014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02107014 about?
NCT02107014 is a clinical study titled "Low Dose Naltrexone (LDN) Immune Monitoring". We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.
What is the current status of trial NCT02107014?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2014-03. Estimated completion is 2014-07.
What interventions are being tested in trial NCT02107014?
The interventions under investigation include: Low Dose Naltrexone (DRUG).
Who is sponsoring clinical trial NCT02107014?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.